Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.
about
Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial componentsThe Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture: What Does The Clinician Need To Know?A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.Time for integrating clinical, lifestyle and molecular data to predict drug responses - Authors' replyInformation about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDsAntibiotic precautions in athletesPerformance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes.Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.Tendon Injury and Fluoroquinolone Use: A Systematic Review.Is pathology necessary to predict mortality among men with prostate-cancer?Operative versus nonoperative treatment for acute Achilles tendon rupture: a meta-analysis based on current evidenceImpact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders.Nutrition for travel.Adiposity and tendinopathy.Predictors of primary Achilles tendon ruptures.Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?BET 2: Do fluoroquinolones increase the incidence of tendinopathy?Spontaneous bilateral Achilles tendon rupture in a patient treated with oral levofloxacin.Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions.Oral and inhaled glucocorticoid use and risk of Achilles or biceps tendon rupture: a population-based case-control study.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.Open repair of the acutely torn Achilles tendon under local anaesthetic.Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database.Management of acute Achilles tendon ruptures
P2860
Q24616291-72A0DA64-1149-4DA9-862F-0F4660B472D6Q24632035-1721A0E8-5C1D-4C87-89F5-6669E9561121Q30812957-4268E562-813E-44CC-A0FE-0E1B2E0E0FF6Q31109187-A8D7AB4A-C1CC-4223-9DFF-44C367E783C9Q33414008-ECC723C9-F973-49E1-AA48-9E0B9A703C84Q33786181-7181F003-600F-4EDE-A413-DB778DB6CF77Q33934896-98E80A9F-2748-4F58-90C7-001422AFD382Q33944898-63A49B01-F4FF-4FBC-B22B-0A2641D16F08Q34226785-7B512DF8-8FAC-420F-956F-1F731F3CA28DQ34359994-92EB2A5D-B0EA-4E2A-BE5D-AED932ACFC4EQ34769040-7A23E785-A697-40AB-8281-DE10A4C6C60AQ35851147-05E4E20F-83FF-4CDC-8BC6-A57856C5B20CQ36412964-AF70A17E-3E27-467A-AA8F-5BFEC8F84955Q37020259-81C45FC4-8EE0-400D-9569-1498A96764F4Q37209851-D65AB802-A368-4355-9196-18AD0AFD0960Q38220281-1F5E0801-D7CE-407A-9526-9432F049DA3EQ38590850-101EAB9B-3523-43F9-9CD0-7ADFD061F29DQ38823701-6A728145-7E8D-4F68-8E4E-55B09448C1D4Q38872753-3A120B3B-6F98-4BFD-997F-5683BB2CBCE5Q38926337-56811EBF-DE4A-4C34-B813-AA9E4BE02DB8Q39980085-4F97D256-2A1E-40F5-A15E-CA556DCED6A8Q41370934-4CE206D4-D9CB-43F9-996B-4E42762EF9ACQ44455948-4FFC3990-E6B8-430B-93BD-995AAB8774BEQ47271377-DAF67501-1B4F-4AB6-8AE2-A03DE04E7CA9Q48190795-053A7741-A66E-46CE-A4DB-49A52C85C33AQ55027036-CF62E2A6-1040-4954-A710-3FEEB4E2A3B2Q59135254-3E760882-F7F3-422A-BA93-9C90680D0432
P2860
Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Achilles tendon rupture and it ...... in a managed care population.
@ast
Achilles tendon rupture and it ...... in a managed care population.
@en
type
label
Achilles tendon rupture and it ...... in a managed care population.
@ast
Achilles tendon rupture and it ...... in a managed care population.
@en
prefLabel
Achilles tendon rupture and it ...... in a managed care population.
@ast
Achilles tendon rupture and it ...... in a managed care population.
@en
P2093
P2860
P356
P1476
Achilles tendon rupture and it ...... in a managed care population.
@en
P2093
Alexander M Walker
Daniel Fife
Gary J Noel
John D Seeger
Larry N Johnson
William A West
P2860
P304
P356
10.1002/PDS.1214
P577
2006-11-01T00:00:00Z